Precision Immunotherapy Improves Organ Dysfunction in Phenotypically Stratified Sepsis Patients

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Journal of the American Medical Association  https://doi.org/10.1001/jama.2025.24175 
Dr. Evangelos J. Giamarellos-Bourboulis  et al.

Points

Researchers stratified sepsis patients into phenotypes of macrophage activation syndrome or immunoparalysis to administer targeted anakinra or interferon gamma therapies respectively.
The study achieved its primary endpoint with thirty-five percent of the treatment group showing significant SOFA score improvements compared to seventeen percent of the placebo group.
Statistical analysis revealed a seventeen percent absolute difference in organ dysfunction improvement between the precision immunotherapy cohort and the standard care control group by day nine.
While organ function improved significantly with targeted therapy, the trial did not observe a statistically significant difference in twenty-eight-day mortality rates between the two groups.
Adverse events remained high across both cohorts with specific increases in anemia for anakinra recipients and hemorrhage for those receiving interferon gamma.

Summary

This randomized, double-blind, placebo-controlled trial evaluated the efficacy of precision immunotherapy in sepsis patients characterized by specific immune dysregulation phenotypes. Conducted across 33 centers, the study stratified 276 patients meeting Sepsis-3 criteria into two distinct cohorts: macrophage activation–like syndrome (ferritin >4420 ng/mL) and sepsis-induced immunoparalysis (ferritin ≤4420 ng/mL and HLA-DR <5000 receptors). Patients exhibiting macrophage activation received intravenous anakinra, while those with immunoparalysis were treated with subcutaneous recombinant human interferon gamma, compared against placebo controls over a 15-day treatment period.

The primary endpoint defined efficacy as a reduction in the mean Sequential Organ Failure Assessment (SOFA) score of at least 1.4 points by day 9 relative to baseline. Results demonstrated that 35.1% of the precision immunotherapy group attained this endpoint compared to only 17.9% in the placebo group, representing a significant absolute risk difference of 17.2% (95% CI, 6.8% to 27.2%; P = .002). This data indicates that biomarker-guided modulation of the host immune response significantly ameliorates organ dysfunction in this high-risk population.

Secondary outcomes revealed no statistically significant difference in 28-day mortality between the intervention and control groups. Safety analysis reported serious treatment-emergent adverse events in 88.8% of participants, with a notable increased incidence of anemia observed in the anakinra arm and hemorrhage in the interferon gamma arm. These findings suggest that targeting specific immune profiles—either by suppressing hyperinflammation or reversing immunoparalysis—offers a viable therapeutic strategy for improving clinical status in sepsis, though further powering is likely required to assess survival benefits.

Link to the article: https://jamanetwork.com/journals/jama/fullarticle/2842634

References

Giamarellos-Bourboulis, E. J., Kotsaki, A., Kotsamidi, I., Efthymiou, A., Koutsoukou, V., Ehler, J., Paridou, A., Frantzeskaki, F., Müller, M. C. A., Pickkers, P., Meylan, S., Nikolopoulos, I., Lupse, M., Gavala, A., Vlachogianni, G., Solomonidi, N., Alevizou, A., Kondili, E., Antoniadou, E., … Tanzarella, E. S. (2025). Precision immunotherapy to improve sepsis outcomes: The immunosep randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2025.24175